Korean Medication Algorithm for Depressive Disorders 2017: Third Revision

키워드

참고문헌 (77)

1. Field M, "Guidelines for clinical practice: from development to use", pp.32~35 (1992), National Academy Press
2. Seo JS, "The Korean Medication Algorithm for Depressive Disorder: second revision", J Affect Disord, 167, pp.312~321 (2014)[DOI]
3. 우영섭, "Cognitive Deficits as a Mediator of Poor Occupational Function in Remitted Major Depressive Disorder Patients", Clinical Psychopharmacology and Neuroscience, 14(1), pp.1~16 (2016), 대한정신약물학회
4. Lee MS, "The Korean Medication Algorithm for Major Depressive Disorder (KMA-MDD): report of the Korean society of depressive and bipolar disorders", Int J Psychiatry Clin Pract, 10, pp.186~194 (2006)[DOI]
5. 서정석, "한국형 우울장애 약물치료 알고리듬 2006 (Ⅰ)", 신경정신의학, 46(5), pp.453~460 (2007), 대한신경정신의학회
6. Fountoulakis KN, "The International College of Neuropsychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), Part 1: background and methods of the development of guidelines", Int J Neuropsychopharmacol, 20, pp.98~120 (2017)
7. Lam RW, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods", Can J Psychiatry, 61, pp.506~509 (2016)[DOI]
8. Moller HJ, "The CINP bipolar algorithm project: Are everything clinical practice and guideline supported clinical decision making in contrast?", 30th CINP World Congress of Neuropsychopharmacology (2016)
9. American Psychiatric Association, "Practice guideline for the treatment of patients with major depressive disorder", APA, ~ (2010)
10. Komossa K, "Second-generation antipsychotics for major depressive disorder and dysthymia", Cochrane Database Syst Rev, (12) (2010)
11. Spielmans GI, "Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes", PLoS Med, 10, pp.e1001403~ (2013)[DOI]
12. Wen XJ, "Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder", Braz J Med Biol Res, 47, pp.605~616 (2014)[DOI]
13. Zhou X, "Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis", Int J Neuropsychopharmacol, 18 (2015)[DOI]
14. Texas medication algorithm project procedural manual: major depressive disorder algorithms, "Suehs B", Texas Department of State Health Services, ~ (2008)
15. Bauer M, "Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders", World J Biol Psychiatry, 14, pp.334~385 (2013)[DOI]
16. Nelson JC, "Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials", Am J Psychiatry, 166, pp.980~991 (2009)[DOI]
17. Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments", Can J Psychiatry, 61, pp.540~560 (2016)[DOI]
18. Lam RW, "Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy", J Affect Disord, 117(Suppl 1), pp.S26~S43 (2009)[DOI]
19. Hee Ryung Wang, "Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines", Clinical Psychopharmacology and Neuroscience, 15(3), pp.199~209 (2017), 대한정신약물학회[DOI]
20. "Treatment of patients with major depression and practical guideline" (2010)[URL]
21. National Institute for Health and Clinical Excellence, "Quick reference guide. Depression: management of depression in primary and secondary care", NICE, ~ (2009)
22. Connolly KR, "If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies", Drugs, 71, pp.43~64 (2011)[DOI]
23. Cipriani A, "Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis", Lancet, 373, pp.746~758 (2009)[DOI]
24. Hansen RA, "Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder", Ann Intern Med, 143, pp.415~426 (2005)[DOI]
25. Papakostas GI, "A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder", Can J Psychiatry, 51, pp.783~790 (2006)[DOI]
26. Watanabe N, "Mirtazapine versus other antidepressive agents for depression", Cochrane Database Syst Rev, (12) (2011)
27. American Psychiatric Association, "Practice guideline for the treatment of patients with major depressive disorder", American Psychiatric Association, ~ (2000)
28. Bauer M, "World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care", World J Biol Psychiatry, 8, pp.67~104 (2007)[DOI]
29. Pacher P, "Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any?", Curr Med Chem, 6, pp.469~480 (1999)
30. Buff DD, "Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease", J Clin Psychiatry, 52, pp.174~176 (1991)
31. Friedman EH, "Fluoxetine-induced bradycardia", J Clin Psychiatry, 52, pp.477~ (1991)
32. Barbui C, "Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies", CMAJ, 180, pp.291~297 (2009)[DOI]
33. "Antidepressant use in children, adolescents, and adults" (2007)[URL]
34. Anderson RJ, "The prevalence of comorbid depression in adults with diabetes: a meta-analysis", Diabetes Care, 24, pp.1069~1078 (2001)[DOI]
35. Rudisch B, "Epidemiology of comorbid coronary artery disease and depression", Biol Psychiatry, 54, pp.227~240 (2003)[DOI]
36. Raison CL, "When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders", Am J Psychiatry, 160, pp.1554~1565 (2003)[DOI]
37. Ohayon MM, "Using chronic pain to predict depressive morbidity in the general population", Arch Gen Psychiatry, 60, pp.39~47 (2003)[DOI]
38. Whyte EM, "Post stroke depression: epidemiology, pathophysiology, and biological treatment", Biol Psychiatry, 52, pp.253~264 (2002)[DOI]
39. Lustman PJ, "Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial", Psychosom Med, 59, pp.241~250 (1997)[DOI]
40. Shelton RC, "The effects of antidepressants on the thyroid axis in depression", Biol Psychiatry, 33, pp.120~126 (1993)[DOI]
41. de Carvalho GA, "Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function", Thyroid, 19, pp.691~697 (2009)[DOI]
42. Mandrioli R, "Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions", Curr Med Chem, 19, pp.1846~1863 (2012)[DOI]
43. Nakajima S, "Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.1983~1989 (2011)[DOI]
44. Sim K, "Prevention of relapse and recurrence in adults with major depressive disorder: systematic review and meta-analyses of controlled trials", Int J Neuropsychopharmacol, 19 (2015)
45. Baldessarini RJ, "Duration of initial antidepressant treatment and subsequent relapse of major depression", J Clin Psychopharmacol, 35, pp.75~76 (2015)[DOI]
46. Modell JG, "Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL", Biol Psychiatry, 58, pp.658~667 (2005)[DOI]
47. 서정석, "한국형 양극성 장애 약물치료 알고리듬 2014: 우울 삽화", 대한정신약물학회지, 25(2), pp.68~78 (2014), 대한정신약물학회
48. Patkar A, "A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state", PLoS One, 7, pp.e34757~ (2012)[DOI]
49. Suppes T, "Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study", Am J Psychiatry, 173, pp.400~407 (2016)[DOI]
50. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders fifth edition (DSM 5)" (2013), American Psychiatric Publishing
51. Baweja R, "Disruptive mood dysregulation disorder: current insights", Neuropsychiatr Dis Treat, 12, pp.2115~2124 (2016)[DOI]
52. Yoo HK, "Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders", Eur Child Adolesc Psychiatry, 20, pp.127~135 (2011)[DOI]
53. Birmaher B, "Practice parameter for the assessment and treatment of children and adolescents with depressive disorders", J Am Acad Child Adolesc Psychiatry, 46, pp.1503~1526 (2007)[DOI]
54. Ghaemi SN, ""Cade's disease" and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder", Can J Psychiatry, 47, pp.125~134 (2002)[DOI]
55. Weisz JR, "Effects of psychotherapy for depression in children and adolescents: a meta-analysis", Psychol Bull, 132, pp.132~149 (2006)[DOI]
56. Klein JB, "Cognitive-behavioral therapy for adolescent depression: a meta-analytic investigation of changes in effect-size estimates", J Am Acad Child Adolesc Psychiatry, 46, pp.1403~1413 (2007)[DOI]
57. Cheung AH, "Guidelines for Adolescent Depression in Primary Care (GLAD-PC): II. Treatment and ongoing management", Pediatrics, 120, pp.e1313~e1326 (2007)[DOI]
58. Hughes CW, "Texas children's medication algorithm project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder", J Am Acad Child Adolesc Psychiatry, 46, pp.667~686 (2007)[DOI]
59. Zuckerbrot RA, "Guidelines for Adolescent Depression in Primary Care (GLAD-PC): I. Identification, assessment, and initial management", Pediatrics, 120, pp.e1299~e1312 (2007)[DOI]
60. Hetrick SE, "Newer generation antidepressants for depressive disorders in children and adolescents", Cochrane Database Syst Rev, 11 (2012)
61. Cipriani A, "Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis", Lancet, 388, pp.881~890 (2016)[DOI]
62. Steffens DC, "Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis", Int J Geriatr Psychiatry, 26, pp.564~572 (2011)[DOI]
63. MacQueen GM, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. special populations: youth, women, and the elderly", Can J Psychiatry, 61, pp.588~603 (2016)[DOI]
64. Owens MJ, "Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites", J Pharmacol Exp Ther, 283, pp.1305~1322 (1997)
65. Sanchez C, "A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?", Int Clin Psychopharmacol, 29, pp.185~196 (2014)[DOI]
66. Alexopoulos GS, "The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients", Postgrad Med, pp.1~86 (2001)
67. 김재민, "Development of a Korean Version of the Perceived Deficits Questionnaire-Depression for Patients with Major Depressive Disorder", Clinical Psychopharmacology and Neuroscience, 14(1), pp.26~32 (2016), 대한정신약물학회
68. Biggs WS, "Premenstrual syndrome and premenstrual dysphoric disorder", Am Fam Physician, 84, pp.918~924 (2011)
69. Le Strat Y, "Child marriage in the United States and its association with mental health in women", Pediatrics, 128, pp.524~530 (2011)[DOI]
70. Zuckerman B, "Depressive symptoms during pregnancy: relationship to poor health behaviors", Am J Obstet Gynecol, 160, pp.1107~1111 (1989)[DOI]
71. Ng RC, "Pharmacologic treatment for postpartum depression: a systematic review", Pharmacotherapy, 30, pp.928~941 (2010)[DOI]
72. Thase ME, "A randomized, double-blind comparison of olanzapine", fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder, 2007, pp.68, 224~236
73. Berman RM, "Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants", CNS Spectr, 14, pp.197~206 (2009)[DOI]
74. El-Khalili N, "Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study", Int J Neuropsychopharmacol, 13, pp.917~932 (2010)[DOI]
75. Molyneaux E, "Antidepressant treatment for postnatal depression", Issues Ment Health Nurs, 38, pp.188~190 (2017)[DOI]
76. Milev RV, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. neurostimulation treatments", Can J Psychiatry, 61, pp.561~575 (2016)[DOI]
77. Ravindran AV, "Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. complementary and alternative medicine treatments", Can J Psychiatry, 61, pp.576~587 (2016)[DOI]

관련 논문AI추천